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OBJECTIVES: To estimate the cost-effectiveness of inﬂiximab
compared to usual treatment for treatment of active psoriatic
arthritis (PSA) over ﬁve-years from a Canadian health care per-
spective. METHODS: A Markov computer simulation model
representing the natural history of severe PSA patients was
designed with a 16 week cycle length. Clinical states were deﬁned
based on number of active (swollen or tender) joints as follows:
1) zero joints; 2) 1–4 active joints; 3) 5–9 joints; and 4) ≥10
joints. The model was stratiﬁed by baseline score on the psoria-
sis area and severity index (PASI) of < and ≥2.5. Transition prob-
abilities to new clinical states were based on results of two
randomized, controlled clinical trials (IMPACT-1 and IMPACT-
2). Direct health care costs (2004 Canadian dollars) and EQ-5D
utilities by active joint states were determined from a sample of
100 PSA patients receiving care in Toronto. The EQ-5D for each
health state was estimated from a regression equation using the
active joint categories, the Health Assessment Questionnaire
(HAQ) and the PASI (adjusted R2 = 0.65). Observed scores in
these parameters from the clinical trials were used to model the
utility values. Costs and outcomes were discounted at 3%. No
mortality beneﬁt was assumed and univariate and probabilistic
sensitivity analyses were performed. RESULTS: At 5mg/kg dose,
each inﬂiximab infusion would cost $3661. The incremental 
cost and quality adjusted life years (QALYs) gained (95% CI) 
of the inﬂiximab strategy were estimated to be $76,600
($53,900–$97,400) and 1.01 (0.58–1.40), respectively. The
incremental cost-effectiveness ratio was estimated to be $75,500
(95% CI $62,000–$100,100) per QALY gained. The model 
was robust to plausible parameter changes. CONCLUSIONS:
Assuming a willingness to pay of $100,000 per QALY gained,
our results show that for PSA patients similar to those included
in the trials, adding inﬂiximab may be economically attractive.
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OBJECTIVE: The highest incidence of asthma occurs in chil-
dren. Proper management requires treatment with multiple
expensive medications. For private drug plan subscribers,
deductibles and co-payments constitute a user fee which may
impede access. The primary objective was to examine the impact
of co-pay level on asthma medication use in asthmatic children
in private drug plans. METHODS: A cohort of 17,046 asthmatic
Ontario children from an aggregated private sector claims data-
base were classiﬁed as zero (no co-payment), low (<20%) or high
(>20%) co-payment. Use of bronchodilators (BD), inhaled cor-
ticosteroids (ICS), leukotriene antagonists (LA), oral corticos-
teroids (OS) and combinations were examined in 2003. Multiple
linear and logistic regressions compared medication use between
groups controlling for age and sex. RESULTS: Annual asthma
medication claims per child were signiﬁcantly lower in the high
co-pay group (6.6) compared to the zero (7.0) and low co-pay
(7.2) groups (p < 0.0001). Children in the high co-pay group
were less likely to receive concomitant BDs, ICSs and LAs com-
pared to the low co-pay group, Odds Ratio 0.78 (95% CI 0.67,
0.86). As a marker for asthma exacerbation, children in the high
co-pay group were more likely to receive an OS compared to 
the zero co-pay group, Odds Ratio 1.1 (95% CI 1.0, 1.2). 
CONCLUSIONS: Cost-sharing level affected asthma medication
utilization, with the highest cost-sharing group exhibiting sig-
niﬁcantly lower use of maintenance medications and higher use
of medications for acute exacerbation than other groups. These
results are valuable to inform decisions regarding policy reform
and drug plan management.
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OBJECTIVES: Recent evidence indicates cholesterol reduction
to levels below currently recommended goals contribute to
further reduction of CHD events. The prescribing pattern of
statins and rate of cholesterol goal attainment in CHD patients
were evaluated at 2 public hospitals in Hong Kong. METHODS:
Retrospective observational study was conducted at 2 hospitals
(A and B). 276 patients were randomly selected from the coro-
nary care units. Patients admitted due to acute myocardial infarc-
tion (AMI) over the period of January 1, 2001 to December 31,
2002 were followed up. Statin therapy must be prescribed for at
least 3 months after initial hospitalization. Treatment patterns
were determined by studying the dosages, titration (if any), and
change of statin therapy. Cholesterol levels were measured before
and after treatment and the NCEP ATP III was used to deﬁne
cholesterol goal (LDL < 2.59mmol/dl). RESULTS: Of the 276
patients, 174 patients (43% female; mean age 63 years [SD 12])
were initiated on statin therapy after admission and studied.
Hospital-A had signiﬁcantly (p < 0.05) more patients prescribed
simvastatin 40mg or higher dose statins compared to hospital-
B. Overall 48% percent of patients did not experience any
change in statin dose, approximately equal number of patients
were down titrated (24%) as were up titrated (27%). The cho-
lesterol goal attainment rate based on calculated LDL-C mea-
sures using the Friedwald equation was 61.62% at A and
37.70% at B. Based on logistic equation model for goal attain-
ment; patients having hypertension (Odds Ratio [OR] 0.41; 95%
CI 0.91–0.87), CHD (OR 0.17; 95% CI 0.03–0.93) and elevated
LDL-C (OR 0.602; 95% 0.407–0.889) at baseline were less
likely to attain goal. CONCLUSION: Current lipid lowering
therapies fail to bring majority of the patients to recommended
cholesterol goal at the 2 hospitals. More effective therapeutic
options are needed to help CHD patients attain recommended
cholesterol goals.
